Duan, Shunlei https://orcid.org/0000-0003-0548-5150
Agger, Karl
Messling, Jan-Erik
Nishimura, Koutarou
Han, Xuerui
Peña-Rømer, Isabel https://orcid.org/0000-0002-2987-6538
Shliaha, Pavel
Damhofer, Helene https://orcid.org/0000-0003-4459-7534
Douglas, Max https://orcid.org/0000-0003-1186-7163
Kohli, Manas https://orcid.org/0000-0002-3904-2158
Pal, Akos
Asad, Yasmin https://orcid.org/0000-0002-3112-8694
Van Dyke, Aaron https://orcid.org/0000-0002-6989-4394
Reilly, Raquel
Köchl, Robert https://orcid.org/0000-0003-3370-5501
Tybulewicz, Victor L. J. https://orcid.org/0000-0003-2439-0798
Hendrickson, Ronald C.
Raynaud, Florence I. https://orcid.org/0000-0003-0957-6279
Gallipoli, Paolo https://orcid.org/0000-0001-7254-2253
Poulogiannis, George https://orcid.org/0000-0002-0529-8614
Helin, Kristian https://orcid.org/0000-0003-1975-6097
Funding for this research was provided by:
Kræftens Bekæmpelse (R167-A10877, R223-A13071)
Novo Nordisk Fonden (NNF17CC0027852)
Institute of Cancer Research, Royal Cancer Hospital
Kirsten and Freddy Johansen’s Research Prize Greater Copenhagen Health Science Partners
Cancer Research UK (C57799/A27964)
Article History
Received: 13 May 2024
Accepted: 8 May 2025
First Online: 27 May 2025
Competing interests
: K.H. and K.A. are co-founders of Dania Therapeutics. K.H. is a scientific advisor for Hannibal Innovation and was recently a scientific advisor for Inthera Bioscience AG and for MetaboMed Inc. The remaining authors declare no competing interests.